All In Biotech

Free tool

FAERS Monitor: Ocrevus Zunovo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761371 or its brand name (Ocrevus Zunovo, Ocrelizumab and Hyaluronidase-Ocsq). Reports on generic versions are filed under their own applications.

Reports

499

Serious

96

19% of reports

Hospitalization

26

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • injection site pain66
  • injection site erythema53
  • fatigue48
  • pain40
  • no adverse event29
  • off label use29
  • headache25
  • multiple sclerosis relapse25
  • rash24
  • contusion23
  • erythema22
  • injection site reaction22
  • swelling18
  • injection site swelling16
  • pruritus14

Reports by year received

View as table
YearReports
20212
202422
2025213
2026262

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,660 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
injection site erythemaSignal5318.014.0839
multiple sclerosis relapseSignal2515.410.5323
injection site reactionSignal2213.59.0243
contusionSignal2310.16.8180
injection site painSignal669.17.2473
injection site swellingSignal168.85.4103
swellingSignal188.15.2106
no adverse eventSignal296.74.7137
erythemaSignal224.53.057
painSignal402.72.044
fatigueSignal482.62.047
rashSignal242.31.617
headache251.71.16
pruritus141.50.92
off label use291.41.03

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.